Dr. Edward Kim on ASCO's TAPUR Trial
Edward S. Kim, MD, chair, Solid Tumor Oncology and Investigational Therapeutics, Donald S. Kim Distinguished Chair for Cancer Research, Levine Cancer Institute, Carolinas HealthCare System, discusses the significance of the TAPUR clinical trial, which is being conducted by ASCO.
Edward S. Kim, MD, chair, Solid Tumor Oncology and Investigational Therapeutics, Donald S. Kim Distinguished Chair for Cancer Research, Levine Cancer Institute, Carolinas HealthCare System, discusses the significance of the TAPUR clinical trial, which is being conducted by ASCO.
TAPUR is the first clinical trial ever conducted by ASCO, which aims to give access of FDA-approved biologic agents to patients, Kim explains. Using a list of mutations obtained via genomic screening, researchers are determining if these agents will elicit activity in patients with these molecular abnormalities in tumor types other than what they are currently approved in.
The trial is currently underway at 37 clinical sites, with additional sites to be added in the upcoming months.
<<<
